Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Anticoagulants"" wg kryterium: Temat


Tytuł :
The Effect of Direct Oral Anticoagulants on Outcomes After Urgent or Emergent Cardiac Surgery.
Autorzy :
Hecht JP; Department of Pharmacy Services, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI. Electronic address: .
Huang J; Department of Pharmacy Services, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI.
Pruitt A; Department of Cardiothoracic Surgery, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI.
Gupta A; Department of Cardiothoracic Surgery, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI.
Clark MJ; Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, MI.
He C; Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, MI.
Brockhaus K; Department of Pharmacy Services, Saint Joseph Mercy Ann Arbor, Ann Arbor, MI.
Pokaż więcej
Źródło :
Journal of cardiothoracic and vascular anesthesia [J Cardiothorac Vasc Anesth] 2022 Dec; Vol. 36 (12), pp. 4273-4280. Date of Electronic Publication: 2022 Sep 11.
Typ publikacji :
Multicenter Study; Journal Article
MeSH Terms :
Anticoagulants*/adverse effects
Cardiac Surgical Procedures*/adverse effects
Humans ; Retrospective Studies ; Hemorrhage ; Platelet Aggregation Inhibitors/therapeutic use ; Administration, Oral
Czasopismo naukowe
Tytuł :
Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications.
Autorzy :
Heestermans M; French Blood Establishment (EFS) Auvergne Rhône Alpes-Scientific Department, F-42270 Saint-Etienne, France.; INSERM, U1059, SAINBIOSE, Jean Monnet University, F-42023 Saint-Etienne, France.
Poenou G; INSERM, U1059, SAINBIOSE, Jean Monnet University, F-42023 Saint-Etienne, France.; Service de Médecine Vasculaire et Thérapeutique, CHU de St-Etienne, F-42055 Saint-Etienne, France.
Hamzeh-Cognasse H; INSERM, U1059, SAINBIOSE, Jean Monnet University, F-42023 Saint-Etienne, France.
Cognasse F; French Blood Establishment (EFS) Auvergne Rhône Alpes-Scientific Department, F-42270 Saint-Etienne, France.; INSERM, U1059, SAINBIOSE, Jean Monnet University, F-42023 Saint-Etienne, France.
Bertoletti L; INSERM, U1059, SAINBIOSE, Jean Monnet University, F-42023 Saint-Etienne, France.; Service de Médecine Vasculaire et Thérapeutique, CHU de St-Etienne, F-42055 Saint-Etienne, France.; INSERM, CIC-1408, CHU Saint-Etienne, F-42055 Saint-Etienne, France.
Pokaż więcej
Źródło :
Cells [Cells] 2022 Oct 13; Vol. 11 (20). Date of Electronic Publication: 2022 Oct 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Venous Thromboembolism*/drug therapy
Humans ; Heparin/pharmacology ; Heparin/therapeutic use ; Blood Coagulation
Czasopismo naukowe
Tytuł :
Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPARγ-modulating ligand.
Autorzy :
Ma L; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Tang J; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Cai G; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Chen F; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Liu Q; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Zhou Z; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Zhang S; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Liu X; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China. Electronic address: .
Hou N; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China. Electronic address: .
Yi W; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation & Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, China. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic chemistry [Bioorg Chem] 2022 Dec; Vol. 129, pp. 106191. Date of Electronic Publication: 2022 Oct 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Dicumarol*/chemistry
Dicumarol*/pharmacology
Dicumarol*/therapeutic use
Hypoglycemic Agents*/chemistry
PPAR gamma*/agonists
Thrombosis*/drug therapy
Thrombosis*/etiology
Anticoagulants*/chemistry
Anticoagulants*/pharmacology
Humans ; Ligands ; Thiazolidinediones/adverse effects ; Thiazolidinediones/pharmacology
Czasopismo naukowe
Tytuł :
Perceptions of patients and healthcare providers on patient education to improve oral anticoagulant management.
Autorzy :
Wang M; Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.; Clinical Pharmacology & Toxicology Research, The Research Institute of St. Joseph's Hamilton, Hamilton, Ontario, Canada.
Swinton M; School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Troyan S; Clinical Pharmacology & Toxicology Research, The Research Institute of St. Joseph's Hamilton, Hamilton, Ontario, Canada.
Ho J; Division of Clinical Pharmacology & Toxicology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Division of Geriatric Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Schlegel Research Institute for Aging, Waterloo, Ontario, Canada.
M Siegal D; Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Mbuagbaw L; Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
Thabane L; Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.; Biostatistics Unit, St Joseph's Healthcare-Hamilton, Hamilton, Ontario, Canada.; School of Public Health, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa.
M Holbrook A; Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.; Clinical Pharmacology & Toxicology Research, The Research Institute of St. Joseph's Hamilton, Hamilton, Ontario, Canada.; Division of Clinical Pharmacology & Toxicology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Journal of evaluation in clinical practice [J Eval Clin Pract] 2022 Dec; Vol. 28 (6), pp. 1027-1036. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :
Journal Article
MeSH Terms :
Anticoagulants*
Patient Education as Topic*
Humans ; Administration, Oral ; Health Personnel ; Ontario
Czasopismo naukowe
Tytuł :
How often are parenteral anticoagulants administered by parents?
Autorzy :
Favaloro EJ; Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.; Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.; School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, New South Wales, Australia.; School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia.
Pasalic L; Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.; Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.; Westmead Clinical School, University of Sydney, Westmead, New South Wales, Australia.
Lippi G; Section of Clinical Biochemistry, University of Verona, Verona, Italy.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2022 Dec; Vol. 20 (12), pp. 2746-2750. Date of Electronic Publication: 2022 Oct 05.
Typ publikacji :
Letter
MeSH Terms :
Anticoagulants*/adverse effects
Heparin, Low-Molecular-Weight*
Humans ; Heparin/adverse effects ; Infusions, Parenteral ; Parents
Opinia redakcyjna
Tytuł :
Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms.
Autorzy :
Saviano A; Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy.
Brigida M; Gastroenterology Unit, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Petruzziello C; Department of Emergency Medicine, San Carlo di Nancy Hospital, GVM Research, 00165 Rome, Italy.
Candelli M; Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy.
Gabrielli M; Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy.
Ojetti V; Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy.; Department of Emergency Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2022 Nov 12; Vol. 23 (22). Date of Electronic Publication: 2022 Nov 12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticoagulants*/adverse effects
Warfarin*/adverse effects
Humans ; Administration, Oral ; Dabigatran/adverse effects ; Gastrointestinal Hemorrhage/chemically induced ; Gastrointestinal Hemorrhage/drug therapy
Czasopismo naukowe
Tytuł :
Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
Autorzy :
Zhang G; Key Laboratory of Chemical Biology (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. .
Yang K; Key Laboratory of Chemical Biology (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. .
Wang L; Key Laboratory of Chemical Biology (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. .
Cheng Y; Key Laboratory of Chemical Biology (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. .
Liu C; Key Laboratory of Chemical Biology (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. .; National Glycoengineering Research Center, Shandong University, Jinan 250012, Shandong, PR China.
Pokaż więcej
Źródło :
Organic & biomolecular chemistry [Org Biomol Chem] 2022 Nov 02; Vol. 20 (42), pp. 8323-8330. Date of Electronic Publication: 2022 Nov 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/chemistry
Heparin, Low-Molecular-Weight*
Heparin/chemistry ; Heparitin Sulfate/chemistry ; Oligosaccharides/chemistry
Czasopismo naukowe
Tytuł :
Oral anticoagulant management of patients with mechanical heart valves at the Salam Centre of Khartoum: Observations on quality of anticoagulation and thrombotic risk.
Autorzy :
Erba N; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Tosetto A; Hematology Department, San Bortolo Hospital, Vicenza, Italy.
Langer M; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Abdallah SA; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Giovanella E; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Lentini S; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Masini F; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Mocini A; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Portella G; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Salvati AC; Medical Division, Emergency, ONG Onlus, Milan, Italy.
Squizzato A; Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy.
Testa S; Hemostasis and Thrombosis Center, Laboratory Medicine Department, ASST Cremona, Cremona, Italy.
Lip GYH; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Poli D; Thrombosis Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. Electronic address: .
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2022 Nov; Vol. 219, pp. 155-161. Date of Electronic Publication: 2022 Sep 21.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anticoagulants*/adverse effects
Thrombosis*/chemically induced
Thrombosis*/etiology
Adult ; Aspirin/pharmacology ; Blood Coagulation ; Female ; Heart Valves ; Hemorrhage/chemically induced ; Humans ; Male
Czasopismo naukowe
Tytuł :
A Historical Perspective on the Reversal of Anticoagulants.
Autorzy :
Salter B; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Crowther M; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Seminars in thrombosis and hemostasis [Semin Thromb Hemost] 2022 Nov; Vol. 48 (8), pp. 955-970. Date of Electronic Publication: 2022 Sep 02.
Typ publikacji :
Review; Journal Article
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Factor Xa*/therapeutic use
Humans ; Administration, Oral ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Hemorrhage/prevention & control ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł :
Marine Biological Macromolecules and Chemically Modified Macromolecules; Potential Anticoagulants.
Autorzy :
Chandika P; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.
Tennakoon P; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Major of Biomedical Engineering, Division of Smart Healthcare and New-Senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Korea.
Kim TH; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.
Kim SC; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Major of Biomedical Engineering, Division of Smart Healthcare and New-Senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Korea.
Je JY; Major of Human Bioconvergence, Division of Smart Healthcare, Pukyong National University, Busan 48513, Korea.
Kim JI; Major of Food Science and Nutrition, Pukyong National University, Busan 48513, Korea.
Lee B; Major of Food Science and Nutrition, Pukyong National University, Busan 48513, Korea.
Ryu B; Major of Food Science and Nutrition, Pukyong National University, Busan 48513, Korea.
Kang HW; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.; Major of Biomedical Engineering, Division of Smart Healthcare and New-Senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Korea.
Kim HW; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.; Department of Marine Biology, Pukyong National University, Busan 48513, Korea.
Kim YM; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.; Major of Food Science and Technology, Pukyong National University, Busan 48513, Korea.
Kim CS; Department of Orthopedic Surgery, Kosin University Gospel Hospital, Busan 49267, Korea.
Choi IW; Department of Microbiology, College of Medicine, Inje University, Busan 47392, Korea.
Park WS; Department of Physiology, Institute of Medical Sciences, School of Medicine, Kangwon National University, Chuncheon 24341, Korea.
Yi M; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.; Major of Biomedical Engineering, Division of Smart Healthcare and New-Senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Korea.
Jung WK; Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Korea.; Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Korea.; Major of Biomedical Engineering, Division of Smart Healthcare and New-Senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Korea.
Pokaż więcej
Źródło :
Marine drugs [Mar Drugs] 2022 Oct 21; Vol. 20 (10). Date of Electronic Publication: 2022 Oct 21.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Thrombosis*/drug therapy
Humans ; Heparin/pharmacology ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Hemorrhage/prevention & control ; Fibrin ; Fibrinogen ; Enzyme Precursors
Czasopismo naukowe
Tytuł :
Preparation, Anticoagulant and Antioxidant Properties of Glucosamine-Heparin Salt.
Autorzy :
Miao Q; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Li Q; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
Tan W; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
Mi Y; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
Ma B; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang J; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
Guo Z; Key Laboratory of Coastal Biology and Bioresource Utilization, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Center for Ocean Mega-Science, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
Pokaż więcej
Źródło :
Marine drugs [Mar Drugs] 2022 Oct 18; Vol. 20 (10). Date of Electronic Publication: 2022 Oct 18.
Typ publikacji :
Journal Article
MeSH Terms :
Heparin*/pharmacology
Heparin*/chemistry
Anticoagulants*/pharmacology
Anticoagulants*/chemistry
Humans ; Antioxidants/pharmacology ; Antioxidants/chemistry ; Glucosamine/pharmacology ; Glucosamine/chemistry ; Sodium Chloride ; Ions ; Electrolytes
Czasopismo naukowe
Tytuł :
Acute Pulmonary Embolism: A Review.
Autorzy :
Freund Y; Sorbonne Université, Improving Emergency Care FHU, Paris, France.; Emergency Department, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Cohen-Aubart F; Sorbonne Université, Improving Emergency Care FHU, Paris, France.; Internal Medicine Department 2, French National Referral Center for Rare Systemic Diseases and Histiocytoses, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Bloom B; Emergency Department, Barts Health NHS Trust, London, United Kingdom.
Pokaż więcej
Źródło :
JAMA [JAMA] 2022 Oct 04; Vol. 328 (13), pp. 1336-1345.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticoagulants*/administration & dosage
Anticoagulants*/therapeutic use
Pulmonary Embolism*/blood
Pulmonary Embolism*/diagnosis
Pulmonary Embolism*/epidemiology
Pulmonary Embolism*/therapy
Acute Disease ; Administration, Oral ; Dabigatran/therapeutic use ; Fibrin Fibrinogen Degradation Products/analysis ; Heparin/therapeutic use ; Humans ; Risk ; Rivaroxaban/therapeutic use ; United States/epidemiology ; Vitamin K/antagonists & inhibitors ; Warfarin/therapeutic use
Czasopismo naukowe
Tytuł :
Effect of anticoagulants on plasma concentration of macrophage migration inhibitory factor: A pilot study.
Autorzy :
Zhu H; Department of Pulmonary and Critical Care Medicine, Zhengzhou Second People's Hospital, Zhengzhou Affiliated Hospital of Jinan University, Zhengzhou, China.; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yan S; Department of Cell Biology, School of Basic and Forensic Medicine, Baotou Medical College, Baotou, China.
Wu J; Department of Pulmonary and Critical Care Medicine, Zhengzhou Second People's Hospital, Zhengzhou Affiliated Hospital of Jinan University, Zhengzhou, China.
Zhang Z; Department of Pulmonary and Critical Care Medicine, Zhengzhou Second People's Hospital, Zhengzhou Affiliated Hospital of Jinan University, Zhengzhou, China.
Xu A; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2022 Oct; Vol. 44 (5), pp. e236-e238. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji :
Letter
MeSH Terms :
Anticoagulants*/pharmacology
Macrophage Migration-Inhibitory Factors*
Case-Control Studies ; Cell Movement ; Humans ; Macrophages ; Pilot Projects
Opinia redakcyjna
Tytuł :
Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations.
Autorzy :
Dinunno CV; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Lopez CN; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Succar L; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Nguyen DT; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
Graviss EA; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
Salazar E; Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Donahue KR; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Pokaż więcej
Źródło :
Pharmacotherapy [Pharmacotherapy] 2022 Oct; Vol. 42 (10), pp. 768-779. Date of Electronic Publication: 2022 Sep 12.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anticoagulants*
Factor Xa Inhibitors*
Administration, Oral ; Factor Xa ; Fibrinolytic Agents/therapeutic use ; Hemorrhage/chemically induced ; Humans ; Retrospective Studies ; Rivaroxaban
Czasopismo naukowe
Tytuł :
To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin.
Autorzy :
Connell NT; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: .
Sylvester KW; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, United States of America.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2022 Oct; Vol. 218, pp. 199-200. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Heparin*/therapeutic use
Drug Monitoring ; Humans ; Partial Thromboplastin Time
Opinia redakcyjna
Tytuł :
Working towards personalized anticoagulation management.
Autorzy :
Nierman MC; Department of Thrombosis and Anticoagulation, Atalmedial Medical Diagnostics Centers, Jan Tooropstraat 138, 1061 AD Amsterdam, The Netherlands.. Electronic address: .
Pokaż więcej
Źródło :
International journal of cardiology [Int J Cardiol] 2022 Oct 01; Vol. 364, pp. 102. Date of Electronic Publication: 2022 Jun 05.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Blood Coagulation*
Humans
Opinia redakcyjna
Tytuł :
Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban.
Autorzy :
Shah PJ; Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Surat, 394350, India. .
Patel MP; Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Surat, 394350, India.
Shah J; Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, India.
Nair AB; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
Kotta S; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Vyas B; Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Surat, 394350, India.
Pokaż więcej
Źródło :
Drug delivery and translational research [Drug Deliv Transl Res] 2022 Dec; Vol. 12 (12), pp. 3029-3046. Date of Electronic Publication: 2022 Apr 25.
Typ publikacji :
Journal Article
MeSH Terms :
Rivaroxaban*
Anticoagulants*
Humans ; Biological Availability ; Adsorption ; Caco-2 Cells ; Solubility ; Tablets/chemistry ; Calorimetry, Differential Scanning ; Excipients
Czasopismo naukowe
Tytuł :
The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial.
Autorzy :
Suwanawiboon B; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Rotchanapanya W; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Mahaprom K; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Thongnoppakhun W; Division of Molecular Genetics, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Lalerd Y; Division of Medical Genetics, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Limwongse C; Division of Medical Genetics, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Sermsathanasawadi N; Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Owattanapanich W; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 95-104.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Anticoagulants/*therapeutic use
Venous Thromboembolism/*drug therapy
Vitamin K Epoxide Reductases/*genetics
Warfarin/*therapeutic use
Adult ; Anticoagulants/administration & dosage ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Prevalence ; Treatment Outcome ; Venous Thromboembolism/genetics ; Warfarin/administration & dosage
Czasopismo naukowe
Tytuł :
Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis.
Autorzy :
Yasuda H; Department of Emergency and Critical Care Medicine, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Oomiya-ku, Saitama-shi, Saitama, 330-8503, Japan. .; Department of Clinical Research Education and Training Unit, Keio University Hospital Clinical and Translational Research Center (CTR), 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. .
Mayumi T; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Okano H; Department of Critical and Emergency Medicine, National Hospital Organization Yokohama Medical Center, Kanazawa, Japan.
Pokaż więcej
Źródło :
Infection [Infection] 2022 Dec; Vol. 50 (6), pp. 1453-1463. Date of Electronic Publication: 2022 Mar 30.
Typ publikacji :
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms :
Anticoagulants*/therapeutic use
COVID-19*/drug therapy
Humans ; Network Meta-Analysis
Czasopismo naukowe
Tytuł :
The safety and efficacy of periprocedural intravenous anticoagulants for acute ischemic stroke patients who underwent endovascular treatment: Sub-analysis of the RESCUE-Japan Registry 2.
Autorzy :
Matsubara H; Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Enomoto Y; Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan.. Electronic address: .
Egashira Y; Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Uchida K; Department of Neurosurgery, Hyogo Medical College of Medicine, Nishinomiya, Japan.
Yamagami H; Department of Stroke Neurology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Sakai N; Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Yoshimura S; Department of Neurosurgery, Hyogo Medical College of Medicine, Nishinomiya, Japan.
Pokaż więcej
Źródło :
Journal of the neurological sciences [J Neurol Sci] 2022 Nov 15; Vol. 442, pp. 120390. Date of Electronic Publication: 2022 Aug 24.
Typ publikacji :
Journal Article
MeSH Terms :
Anticoagulants*/therapeutic use
Brain Ischemia*/drug therapy
Brain Ischemia*/surgery
Endovascular Procedures*/adverse effects
Endovascular Procedures*/methods
Ischemic Stroke*/drug therapy
Ischemic Stroke*/surgery
Humans ; Heparin/therapeutic use ; Intracranial Hemorrhages/etiology ; Intracranial Hemorrhages/prevention & control ; Japan/epidemiology ; Registries ; Tissue Plasminogen Activator/therapeutic use ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies